ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
百济神州
225.77
+5.82
2.65%
盘前:
226.53
0.7600
+0.34%
04:01 EDT
成交量:
52.79万
成交额:
1.18亿
市值:
243.96亿
市盈率:
-60.97
高:
226.59
开:
223.88
低:
220.64
收:
219.95
数据加载中...
总览
公司
新闻
公告
美股异动 | 百济神州(ONC.US)涨逾3% 2024年收入同比增长55%
智通财经
·
04-30
百济神州在美国专利纠纷中获胜,USPTO裁定相关专利无效
新浪财经
·
04-30
百济神州在美赢得专利诉讼,艾伯维Pharmacyclics公司专利判无效
财经涂鸦
·
04-30
百济神州:Pharmacyclics诉讼所涉专利被裁定无效
中新经纬
·
04-30
创新药产业链表现良好,百济神州、诺诚健华、恒瑞医药等持续活跃
动脉网
·
04-30
百济神州“泽布替尼”专利侵权案胜诉
医药魔方Info
·
04-30
回港中概股午后走强,金山云涨超13%,百济神州涨超7%,万国数据涨超6%,宝尊电商、BOSS直聘涨超2%。
金融界
·
04-30
回港中概股午后走强,金山云(03896.HK)涨超13%,百济神州(06160.HK)涨超7%,万国数据(09698.H
美港电讯
·
04-30
A股创新药概念持续走强,百济神州、诺诚健华、锦波生物均创出历史新高,科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨
美港电讯
·
04-30
百济神州:盘中涨超 5% 24 年收入增 55%
和讯网
·
04-30
百济神州美股专利纠纷胜诉午盘涨近6%
iDoNews
·
04-30
【港股午评:AI股强势,恒生科技指数涨超1%,金山云飙升15%】截至半日收盘,恒指涨0.22%报22056点,恒生科技指数涨1.06%,国企指数跌0.37%。恒指半日成交1127亿港元,南下资金半日净买入港股34.34亿港元。 首季盈利表现逊预期,内银股集体下挫,盛京银行跌超6%,工商银行、邮储银行、招商银行、农业银行跌超4%,建设银行跌近4%。 AI概念股集体走强,金山云大涨超15%,迈富时涨超8%,第四范式涨超6%,美图、金山软件涨超5%,小米涨近5%。小米今天开源首个为推理(Reasoning)而生的大模型“Xiaomi MiMo”,联动预训练到后训练,全面提升推理能力。 机器人概念股集体走强,微创机器人涨超9%,速腾聚创涨超7%。工信部近日表示,人形机器人是人工智能赋能新型工业化的高级载体,将推动人形机器人产业创新发展,以人形机器人小切口带动人工智能大产业发展,高水平赋能新型工业化。 百济神州涨超5%;美药企专利指控被判无效。 迪生创建(0113.HK)获主席潘迪生溢价50.6%提私有化,今日复牌大涨,半日收涨43.1%。 友邦涨近6%;首季新业务价值升13%至15亿美元,香港业务新业务价值升16%。
金融界
·
04-30
百济神州午前涨近6% 美国专利纠纷胜诉公司去年业绩取得强劲增长
新浪港股
·
04-30
港股医药高开低走,恒生医药ETF一度涨超1%
Ofweek维科网
·
04-30
港股异动 | 百济神州(06160)涨超6% 美国专利纠纷胜诉 公司去年业绩取得强劲增长
智通财经
·
04-30
港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(099
美港电讯
·
04-30
夜盘异动丨百济神州涨超6%,美药企专利指控被判无效
老虎资讯综合
·
04-30
百济神州4月29日成交额为7993.13万美元
市场透视
·
04-30
百济神州美国专利纠纷胜诉,创新药沪深港ETF涨超1%,创新药龙头拐点或现?
每日经济新闻
·
04-30
港股创新药板块盘初拉升,百济神州涨超6%
南方财经网
·
04-30
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":225.77,"timestamp":1747339200000,"preClose":219.95,"halted":0,"volume":527903,"hourTrading":{"tag":"盘前","latestPrice":226.53,"preClose":225.77,"latestTime":"04:01 EDT","volume":38,"amount":8608.14,"timestamp":1747382479003},"delay":0,"floatShares":69370116,"shares":108055817,"eps":-3.70325,"marketStatus":"盘前交易","change":5.82,"latestTime":"05-16 05:59:27 EDT","open":223.88,"high":226.59,"low":220.64,"amount":118475918.85832,"amplitude":0.027052,"askPrice":232.12,"askSize":12,"bidPrice":226,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747402200000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":225.77,"preHourTrading":{"tag":"盘前","latestPrice":226.53,"preClose":225.77,"latestTime":"04:01 EDT","volume":38,"amount":8608.14,"timestamp":1747382479003},"postHourTrading":{"tag":"盘后","latestPrice":225.77,"preClose":225.77,"latestTime":"17:47 EDT","volume":76189,"amount":17201187.86,"timestamp":1747345633414},"volumeRatio":1.2605037401514483,"impliedVol":0.4035,"impliedVolPercentile":0.1739},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":69370116,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.2605037401514483,"shares":108055817,"dividePrice":0,"high":226.59,"amplitude":0.027052,"preClose":219.95,"low":220.64,"week52Low":141.31,"pbRate":"6.97","psRate":"5.84","week52High":287.88,"institutionHeld":0,"latestPrice":225.77,"committee":-0.411765,"eps":-3.70325,"divideRate":0,"volume":527903,"delay":0,"ttmEps":-3.70325,"open":223.88,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":235.94,"twentyDayClose":228.14,"sixtyDayClose":236.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531205560","title":"美股异动 | 百济神州(ONC.US)涨逾3% 2024年收入同比增长55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531205560","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531205560?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 21:59","pubTimestamp":1746021564,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周三,百济神州涨逾3%,报259美元。财报显示,百济神州2024年实现收入合计约38.1亿美元,同比增长约55%;产品收入同比增长约72.6%至约38亿美元。4月30日早间,百济神州公告,美国专利商标局作出了一项最终书面决定,宣布Pharmacyclics在‘803 专利授权后复审程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提起上诉。公司表示,百悦泽是其原研药品,公司将对此类专利侵权指控进行坚决的辩护。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0307460666.USD","06160","LU2328871848.SGD","BK1500","BK0239","ONC","BK1583","BK1588","LU0588546209.SGD","688235","BK4139","LU1969619763.USD"],"gpt_icon":0},{"id":"2531031201","title":"百济神州在美国专利纠纷中获胜,USPTO裁定相关专利无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031201","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031201?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 20:10","pubTimestamp":1746015004,"startTime":"0","endTime":"0","summary":"4月30日,百济神州公告表示,美国专利商标局近日作出决定,宣告Pharmacyclics公司持有的第11672803号美国专利全部权利要求无效。这一裁定源于百济神州及其美国子公司与Pharmacyclics之间的一场专利纠纷。面对指控,百济神州迅速作出反应,于2023年11月向USPTO提交专利授权后复审申请,对“803专利”的合法性提出质疑。同时,法院也暂缓了侵权诉讼的审理,以待USPTO的裁决结果。基于以上理由,USPTO最终裁定“803专利”全部权利要求无效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430201652974b8dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","ONC","688235"],"gpt_icon":0},{"id":"2531087307","title":"百济神州在美赢得专利诉讼,艾伯维Pharmacyclics公司专利判无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531087307","media":"财经涂鸦","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531087307?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:52","pubTimestamp":1745995963,"startTime":"0","endTime":"0","summary":"“诉讼目前未对百悦泽在美国的研发和销售产生不利影响。”此前,2023年6月13日,Pharmacyclics向美国特拉华州地方法院提起诉讼,指控百济神州及其全资子公司相关活动导致百悦泽对其“803专利”造成侵权。而泽布替尼与艾伯维/Pharmacyclics重磅药物依布替尼同属BTK抑制剂系列,两款产品有直接竞争关系。Pharmacyclics可对USPTO的最终书面决定提起上诉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043015171594e89cd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","ABBV","BK0239","688235"],"gpt_icon":0},{"id":"2531056717","title":"百济神州:Pharmacyclics诉讼所涉专利被裁定无效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531056717","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531056717?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:16","pubTimestamp":1745993763,"startTime":"0","endTime":"0","summary":"中新经纬4月30日电 30日早间,百济神州发布一则涉及诉讼的公告。该诉讼起源于2023年6月,美国生物制药公司艾伯维旗下的Pharmacyclics公司指控百济神州的药物泽布替尼侵犯专利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430153826974b3fdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","ONC","06160","688235"],"gpt_icon":0},{"id":"2531722937","title":"创新药产业链表现良好,百济神州、诺诚健华、恒瑞医药等持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2531722937","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531722937?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 14:14","pubTimestamp":1745993640,"startTime":"0","endTime":"0","summary":"创新药产业链表现强劲,多家企业如百济神州、诺诚健华和恒瑞医药等持续活跃。百济神州2024年营收同比增长56.19%,核心产品泽布替尼和替雷利珠单抗收入显著增长,预计2025年实现全年经营利润为正。诺诚健华的BCL2抑制剂ICP-248片拟纳入突破性治疗品种,奥布替尼新适应症获批用于一线治疗CLL/SLL。锦波生物2024年营收同比增长84.92%。机构看好创新药产业链在2024年的持续良好表现,认为医药行业将迎来结构性机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430142522974b2a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327148.USD","BK0060","06160","BK0183","BK0012","BK0188","LU1064131003.USD","LU2488822045.USD","LU1064130708.USD","LU1328615791.USD","ONC","BK0028","LU0405327494.USD","600276","BK0239","LU2148510915.USD","09969","LU1969619763.USD","688235","688428","159992","BK0196","LU2328871848.SGD"],"gpt_icon":0},{"id":"2531708753","title":"百济神州“泽布替尼”专利侵权案胜诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708753","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531708753?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:59","pubTimestamp":1745992799,"startTime":"0","endTime":"0","summary":"4月30日,百济神州宣布,美国专利商标局(USPTO)作出了一项最终书面决定,宣布艾伯维旗下Pharmacyclics LLC在专利授权后复审(PGR)程序中受到百济神州质疑的第11672803号美国专利(‘803专利)的全部权利无效。Pharmacyclics可对USPTO的最终书面决定提出上诉。该诉讼经过如下:2023年6月15日,Pharmacyclics指控百济神州BTK抑制剂百悦泽(泽布","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430152124a6ce73a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0},{"id":"2531377644","title":"回港中概股午后走强,金山云涨超13%,百济神州涨超7%,万国数据涨超6%,宝尊电商、BOSS直聘涨超2%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531377644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531377644?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:36","pubTimestamp":1745991360,"startTime":"0","endTime":"0","summary":"回港中概股午后走强,金山云涨超13%,百济神州涨超7%,万国数据涨超6%,宝尊电商、BOSS直聘涨超2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30133650037219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06160","BK1586","BK1613","BK4531","BK4614","BK4505","BK4502","BK1588","BK4607","BK1517","BZ","03888","09698","TTTN","688235","ONC","LU0307460666.USD","BK1589","BK1607","LU1023057109.AUD","BK4509","LU0359201612.USD","BK4122","BK1518","LU2039709279.SGD","BK1500","BK1583","LU0348766576.USD","BK4585","BK4077","LU1688375341.USD","BK4220","BK4551","LU0359202008.SGD","BK0239","BK4563","BK4503","GDS","BK4608","BK1585","LU0588546209.SGD","LU0348767384.USD","LU1969619763.USD","BK1526","BZUN","BK1575","BK4588","BK1134"],"gpt_icon":0},{"id":"2531754057","title":"回港中概股午后走强,金山云(03896.HK)涨超13%,百济神州(06160.HK)涨超7%,万国数据(09698.H","url":"https://stock-news.laohu8.com/highlight/detail?id=2531754057","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531754057?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:33","pubTimestamp":1745991202,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"02ef7766aaeb258258a594519db630be","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1502","BK1583","BK4535","BK4551","09698","03888","09991","06160","BK1526","BK1585","BK1501","TTTN","GDS","688235","BK1586","BK4503","BK4607","BK1517","03896","KC","BK4509","BK4608","BK4220","BK1589","BK1607","BK4529","ONC","BK1518","BK1249","BK4077","BK4614","BK4526","BK1531","BK1588","LU1023057109.AUD","BZ","BK4505","BK1500","BK4122","02076","BK0239","BK1142","BK4558","LU2328871848.SGD","LU0348767384.USD","LU2039709279.SGD","LU0359201612.USD","BZUN","BK4502","BK4563"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强,百济神州、诺诚健华、锦波生物均创出历史新高,科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531735757?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","688382","BK1588","159982","BK0175","002422","688235","BK1583","000963","BK4139","LU0405327148.USD","600276","BK0188","LU1328615791.USD","LU0588546209.SGD","LU2148510915.USD","06160","159992","BK0028","09969","BK0209","BK0060","LU1969619763.USD","BK1161","BK0012","BK0183","BK0187","BK1500","BK0196","LU1064130708.USD","399300","LU1064131003.USD","LU2328871848.SGD","BK0132","BK0239","BK1574","LU0307460666.USD","688266","LU2488822045.USD","688428","LU0405327494.USD","ONC"],"gpt_icon":0},{"id":"2531771649","title":"百济神州:盘中涨超 5% 24 年收入增 55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531771649","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531771649?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 12:42","pubTimestamp":1745988165,"startTime":"0","endTime":"0","summary":"百济神州盘中涨超 6%,截至发稿,股价上涨 5.50%,现报 157.20 港元,成交额 5.72 亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135427974b21a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2531560727","title":"百济神州美股专利纠纷胜诉午盘涨近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531560727","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531560727?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 12:07","pubTimestamp":1745986022,"startTime":"0","endTime":"0","summary":"4月30日,百济神州股价午盘涨5.50%,报157.20港元。美国专利商标局宣布Pharmacyclics的‘803专利全部权利无效,公司原研药百悦泽®未侵权。去年百济神州收入38.1亿美元,同比增长55%,产品收入增长72.6%。强劲业绩得益于百悦泽®的成功及丰富的肿瘤管线,预计2025年将有多个项目数据读出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043012102594e86d2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2531404722","title":"【港股午评:AI股强势,恒生科技指数涨超1%,金山云飙升15%】截至半日收盘,恒指涨0.22%报22056点,恒生科技指数涨1.06%,国企指数跌0.37%。恒指半日成交1127亿港元,南下资金半日净买入港股34.34亿港元。 首季盈利表现逊预期,内银股集体下挫,盛京银行跌超6%,工商银行、邮储银行、招商银行、农业银行跌超4%,建设银行跌近4%。 AI概念股集体走强,金山云大涨超15%,迈富时涨超8%,第四范式涨超6%,美图、金山软件涨超5%,小米涨近5%。小米今天开源首个为推理(Reasoning)而生的大模型“Xiaomi MiMo”,联动预训练到后训练,全面提升推理能力。 机器人概念股集体走强,微创机器人涨超9%,速腾聚创涨超7%。工信部近日表示,人形机器人是人工智能赋能新型工业化的高级载体,将推动人形机器人产业创新发展,以人形机器人小切口带动人工智能大产业发展,高水平赋能新型工业化。 百济神州涨超5%;美药企专利指控被判无效。 迪生创建(0113.HK)获主席潘迪生溢价50.6%提私有化,今日复牌大涨,半日收涨43.1%。 友邦涨近6%;首季新业务价值升13%至15亿美元,香港业务新业务价值升16%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531404722","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531404722?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 12:06","pubTimestamp":1745986017,"startTime":"0","endTime":"0","summary":"恒指半日成交1127亿港元,南下资金半日净买入港股34.34亿港元。AI概念股集体走强,金山云大涨超15%,迈富时涨超8%,第四范式涨超6%,美图、金山软件涨超5%,小米涨近5%。机器人概念股集体走强,微创机器人涨超9%,速腾聚创涨超7%。百济神州涨超5%;美药企专利指控被判无效。迪生创建获主席潘迪生溢价50.6%提私有化,今日复牌大涨,半日收涨43.1%。友邦涨近6%;首季新业务价值升13%至15亿美元,香港业务新业务价值升16%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30120650034703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03888","03968","02833","03143","601658","01658","06682","688235","02066","06160","KSFTF","600036","LU1242518857.USD","81810","02556","HSCEI","HSTECH","BK0188","HHImain","00939","513600","LU1979443071.USD","00113","YANG","LU0456827905.SGD","01357","601398","161631","MCHmain","LU0384037296.USD","02252","601939","LU1115378108.SGD","IE00BYV24P56.USD","01398","HSI","LU0469268626.HKD","HXXD.SI","LU1807302812.USD","01288","LU0259732245.USD","ONC","601288"],"gpt_icon":1},{"id":"2531724435","title":"百济神州午前涨近6% 美国专利纠纷胜诉公司去年业绩取得强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2531724435","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531724435?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 11:52","pubTimestamp":1745985120,"startTime":"0","endTime":"0","summary":" 百济神州盘中涨超6%,截至发稿,股价上涨5.50%,现报157.20港元,成交额5.72亿港元。公司全年业绩取得强劲增长,充分彰显了公司作为全球肿瘤治疗领导者的实力。这得益于百悦泽的持续成功以及公司在肿瘤领域开发的最丰富的实体瘤管线之一,预计2025年将有多个项目进行数据读出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-30/doc-ineuxfhw3485583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU1969619763.USD","BK1500","688235","06160","LU0588546209.SGD","BK4139","ONC","LU2328871848.SGD","BK1583","BK0239","LU0307460666.USD","BK1588"],"gpt_icon":0},{"id":"2531972101","title":"港股医药高开低走,恒生医药ETF一度涨超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531972101","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531972101?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 11:45","pubTimestamp":1745984701,"startTime":"0","endTime":"0","summary":"美国专利商标局最终裁定Pharmacyclics的803专利全部权利无效,该专利此前被用于指控百济神州的百悦泽侵权。4月30日早盘,百济神州大涨超5%,带动港股医药板块上涨,恒生医药ETF(159892)一度涨超1%,持仓股方舟健客涨超10%,乐普生物、荣昌生物等跟涨。银河证券认为,医药板块经历较长时间调整,整体估值处于较低水平,且公募持仓低配,2025年在支持引导商保发展的政策背景下,支付端有望边际改善,创新药械有望获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011450394e86577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043011450394e86577&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK4139","688235","ONC"],"gpt_icon":0},{"id":"2531721243","title":"港股异动 | 百济神州(06160)涨超6% 美国专利纠纷胜诉 公司去年业绩取得强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2531721243","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531721243?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 11:36","pubTimestamp":1745984193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百济神州涨超6%,截至发稿,涨6.04%,报158港元,成交额5.47亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU2328871848.SGD","BK4139","LU1969619763.USD","BK1161","LU0307460666.USD","688235","ONC","BK1583","BK0239","BK1588","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2531726021","title":"港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(099","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726021","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531726021?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 11:11","pubTimestamp":1745982713,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","07226","BK1191","BK1588","BK4614","06160","BK0239","BK1574","BK0028","BK4139","LU2328871848.SGD","HSTECH","300347","BK0077","LU1820825898.SGD","688235","LU0588546209.SGD","BK0216","BK1500","HSCEI","YANG","BK0174","LU1146622755.USD","LU1969619763.USD","ONC","BK1576","BK1161","03347","688428","06185","09969","BK1515","LU0307460666.USD","BK1141"],"gpt_icon":0},{"id":"1173388278","title":"夜盘异动丨百济神州涨超6%,美药企专利指控被判无效","url":"https://stock-news.laohu8.com/highlight/detail?id=1173388278","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173388278?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 10:24","pubTimestamp":1745979873,"startTime":"0","endTime":"0","summary":"4月30日,百济神州夜盘涨超6,消息方面:百济神州称美国专利商标局宣布Pharmacyclics针对百济神州的专利无效。集团宣布,美国专利商标局作出了一项最终书面决定,宣布Pharmacyclics LLC在专利授权後复审程序中受到百济神州质疑的第11,672,803号美国专利的全部权利无效。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"百济神州:美药企专利指控被判无效","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","06160"],"gpt_icon":0},{"id":"2531728003","title":"百济神州4月29日成交额为7993.13万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531728003","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531728003?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 10:17","pubTimestamp":1745979436,"startTime":"0","endTime":"0","summary":"美东时间2025年4月29日,百济神州成交额为7993.13万美元,成交额较昨日增加28.30%,当日成交量为32.12万股。百济神州于2025年4月29日涨0.12%,报249.77美元,该股过去5个交易日跌1.19%,年初至今涨35.22%,过去60日涨11.01%。百济神州有自己的团队进行全球临床试验。截至2023年,百济神州的核心药物是百悦泽,这是一种治疗各种血癌的小分子药物,占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101725a6ce277e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101725a6ce277e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2531972824","title":"百济神州美国专利纠纷胜诉,创新药沪深港ETF涨超1%,创新药龙头拐点或现?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531972824","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531972824?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 10:13","pubTimestamp":1745979209,"startTime":"0","endTime":"0","summary":"消息面,百济神州2025年4月30日公告称,美国专利商标局作出了一项最终书面决定,宣布Pharmacyclics LLC在专利授权后复审程序中受到公司质疑的第11,672,803号美国专利的全部权利无效。受利好刺激,创新药板块盘初拉升,相关ETF——创新药沪深港ETF涨超1%,年初至今涨近14%。相关机构表示,百济神州获胜意味着中国创新药国际化之路取得了阶段性胜利,这也是真正成为具有国际竞争力的MNC的必经过程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK1574","BK1583","06978","LU1969619763.USD","LU0588546209.SGD","LU2328871848.SGD","BK1161","06160","BK1588","LU0307460666.USD","BK1500","ONC"],"gpt_icon":0},{"id":"2531400737","title":"港股创新药板块盘初拉升,百济神州涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531400737","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531400737?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 09:48","pubTimestamp":1745977688,"startTime":"0","endTime":"0","summary":"南方财经4月30日电,港股创新药板块盘初拉升,百济神州涨超6%,石药集团、荣昌生物涨超3%,泰格医药、白云山、君实生物跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394091766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0588546209.SGD","YANG","BK1500","LU1969619763.USD","HSCEI","BK1574","HSTECH","LU0307460666.USD","LU2328871848.SGD","ONC","BK4614","BK1161","06160","BK1588","BK1583","BK4139","06978"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-15","current":-60.573233,"percent":0.055556,"low":-64.911375,"twenty":-43.435784,"median":-39.777828,"eighty":-28.825561,"high":-22.805663,"avg":-37.671721,"sd":9.718771,"marketCap":23766876949},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-15","current":-60.573233,"twenty":-43.435784,"median":-39.777828,"eighty":-28.825561,"marketCap":23766876949}],"updateTime":1747389568254}}}